Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective

Drug Resistance Updates

Volumn 14, Issue 2, 2011, Pages 107-117

  Mouton, Johan W ^a,b   Ambrose, Paul G ^c   Canton, Rafael ^d   Drusano, George L ^e   Harbarth, Stephan ^f   MacGowan, Alasdair ^g   Theuretzbacher, Ursula ^h   Turnidge, John ⁱ  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e Ordway Research Institute   (United States)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g SOUTHMEAD HOSPITAL   (United Kingdom)

^h Center For Anti Infective Agents Vienna   (Austria)

ⁱ WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

Breakpoints; Drug development; Emergence resistance; PK PD

Indexed keywords

ANTIBIOTIC AGENT; LOMEFLOXACIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EXPOSURE; HUMAN; IMMUNE SYSTEM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; RATS;

EID: 79955766026     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2011.02.005     Document Type: Conference Paper

References (86)

1. P.G. Ambrose Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists Pharmacotherapy 26 2006 129 134 (Pubitemid 43082933)
2. P.G. Ambrose, S.M. Bhavnani, C.M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G.L. Drusano Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore Clin. Infect. Dis. 44 2007 79 86 (Pubitemid 44968990)
3. P.G. Ambrose, and D.M. Grasela The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae Diag. Microbiol. Infect. Dis. 38 2000 151 157
4. C.T. Bergstrom, M. Lo, and M. Lipsitch Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals Proc. Natl. Acad. Sci. U.S.A. 101 2004 13285 13290 (Pubitemid 39209657)
5. S.V. Bhat, A.Y. Peleg, T.P. Lodise Jr.; K.A. Shutt, B. Capitano, B.A. Potoski, and D.L. Paterson Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms Antimicrob. Agents Chemother. 51 2007 4390 4395 (Pubitemid 350209894)
6. S.M. Bhavnani, J.P. Hammel, B.B. Cirincione, M.A. Wikler, and P.G. Ambrose Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem Antimicrob. Agents Chemother. 49 2005 3944 3947 (Pubitemid 41233056)
7. J. Blazquez Hypermutation as a factor contributing to the acquisition of antimicrobial resistance Clin. Infect. Dis. 37 2003 1201 1209 (Pubitemid 37372510)
8. P.L. Bonate A brief introduction to Monte Carlo simulation Clin. Pharmacokinet. 40 2001 15 22 (Pubitemid 32182111)
9. D.W. Bratzler, P.M. Houck, C. Richards, L. Steele, E.P. Dellinger, D.E. Fry, C. Wright, A. Ma, K. Carr, and L. Red Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project Arch. Surg. 140 2005 174 182 (Pubitemid 40229109)
10. E.M. Brown, and D. Nathwani Antibiotic cycling or rotation: a systematic review of the evidence of efficacy J. Antimicrob. Chemother. 55 2005 6 9 (Pubitemid 40192608)
11. I. Chopra, A.J. O'Neill, and K. Miller The role of mutators in the emergence of antibiotic-resistant bacteria Drug Resist Update 6 2003 137 145 (Pubitemid 36890338)
12. M. Christ-Crain, D. Stolz, R. Bingisser, C. Muller, D. Miedinger, P.R. Huber, W. Zimmerli, S. Harbarth, M. Tamm, and B. Muller Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial Am. J. Respir. Crit. Care Med. 174 2006 84 93 (Pubitemid 43955248)
13. R. Chuanchuen, K. Beinlich, T.T. Hoang, A. Becher, R.R. Karkhoff-Schweizer, and H.P. Schweizer Cross-resistance between Triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants Overexpressing MexCD-OprJ Antimicrob. Agents Chemother. 45 2001 428 432 (Pubitemid 32105276)
14. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin. Infect. Dis. 26 1998 1 10 quiz 11-2
15. E.M.C. D'Agata, M. Dupont-Rouzeyrol, P. Magal, D. Olivier, and S. Ruan The impact of different antibiotic regimens on the emergence of antimicrobial-resistant bacteria PLoS ONE 3 2008 e4036
16. P. Damas, J.-L. Canivet, D. Ledoux, M. Monchi, P. Melin, M. Nys, and P. De Mol Selection of resistance during sequential use of preferential antibiotic classes Intens. Care Med. 32 2006 67 74 (Pubitemid 43039378)
17. J.G. den Hollander, A.M. Horrevorts, M.L. van Goor, H.A. Verbrugh, and J.W. Mouton Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model Antimicrob. Agents Chemother. 41 1997 95 100 (Pubitemid 26428140)
18. M. Dettenkofer, D.H. Forster, W. Ebner, P. Gastmeier, H. Ruden, and F.D. Daschner The practice of perioperative antibiotic prophylaxis in eight German hospitals Infection 30 2002 164 167 (Pubitemid 34606714)
19. G.L. Drusano Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' Nat. Rev. Microbiol. 2 2004 289 300 (Pubitemid 39490099)
20. G.L. Drusano, D.Z. D'Argenio, S.L. Preston, C. Barone, W. Symonds, S. LaFon, M. Rogers, W. Prince, A. Bye, and J.A. Bilello Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir Antimicrob. Agents Chemother. 44 2000 1655 1659 (Pubitemid 30340810)
21. G.L. Drusano, C. Fregeau, W. Liu, D.L. Brown, and A. Louie Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model Antimicrob. Agents Chemother. 54 2010 4368 4372
22. G.L. Drusano, D.E. Johnson, M. Rosen, and H.C. Standiford Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis Antimicrob. Agents Chemother. 37 1993 483 490 (Pubitemid 23072592)
23. G.L. Drusano, W. Liu, D.L. Brown, L.B. Rice, and A. Louie Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus J. Infect. Dis. 199 2009 219 226
24. G.L. Drusano, W. Liu, C. Fregeau, R. Kulawy, and A. Louie Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant Antimicrob. Agents Chemother. 53 2009 2266 2273
25. G.L. Drusano, S.L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W.A. Craig Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint Antimicrob. Agents Chemother. 45 2001 13 22 (Pubitemid 32039087)
26. H. Eagle, R. Fleischman, and A.D. Musselman Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels Am. J. Med. 9 1950 280 299
27. A.A. Firsov, S.N. Vostrov, I.Y. Lubenko, K. Drlica, Y.A. Portnoy, and S.H. Zinner In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus Antimicrob. Agents Chemother. 47 2003 1604 1613 (Pubitemid 36548544)
28. J.P. Gisbert, X. Calvet, A. O'Connor, F. Mégraud, and C.A. O'Morain Sequential therapy for Helicobacter pylori eradication: a critical review J. Clin. Gastroenterol. 44 2010 313 325 10.1097/MCG. 0b013e3181c8a1a3
29. I.C. Gyssens Quality measures of antimicrobial drug use Int. J. Antimicrob. Agents 17 2001 9 19 (Pubitemid 32008654)
30. A.M. Hammerum, M.A. Toleman, F. Hansen, B. Kristensen, C.H. Lester, T.R. Walsh, and K. Fuursted Global spread of New Delhi metallo-beta-lactamase 1 Lancet Infect. Dis. 10 2010 829 830
31. S. Harbarth, W.C. Albrich, and B. Muller When once is not enough - further evidence of procalcitonin-guided antibiotic stewardship Crit. Care 13 2009 165
32. S. Harbarth, and M.H. Samore Antimicrobial resistance determinants and future control Emerg. Infect. Dis. 11 2005 794 801 (Pubitemid 40720837)
33. S. Harbarth, M.H. Samore, D. Lichtenberg, and Y. Carmeli Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance Circulation 101 2000 2916 2921 (Pubitemid 30415881)
34. F. Harrison, and A. Buckling Hypermutability impedes cooperation in pathogenic bacteria Curr. Biol. 15 2005 1968 1971 (Pubitemid 41566146)
35. T.L. Hedrick, A.S. Schulman, S.T. McElearney, R.L. Smith, B.R. Swenson, H.L. Evans, J.D. Truwit, W.M. Scheld, and R.G. Sawyer Outbreak of resistant Pseudomonas aeruginosa infections during a quarterly cycling antibiotic regimen Surg. Infect. 9 2008 139 152 (Pubitemid 351563817)
36. W.C. Huskins, K. Ba-Thike, M.R. Festin, S. Limpongsanurak, P. Lumbiganon, A. Peedicayil, M. Purwar, S. Shenoy, D.A. Goldmann, and J.E. Tolosa An international survey of practice variation in the use of antibiotic prophylaxis in cesarean section Int. J. Gynaecol. Obstet. 73 2001 141 145 (Pubitemid 32385370)
37. ISO, 2006. ISO 20776-1. Clinical Laboratory Testing and in vitro diagnostic tet systems - susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility testing devices- Part 1.; International Standards Organisation.
38. N. Jumbe, A. Louie, R. Leary, W. Liu, M.R. Deziel, V.H. Tam, R. Bachhawat, C. Freeman, J.B. Kahn, K. Bush, M.N. Dudley, M.H. Miller, and G.L. Drusano Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy J. Clin. Invest. 112 2003 275 285 (Pubitemid 38056363)
39. G. Kahlmeter, D.F. Brown, F.W. Goldstein, A.P. MacGowan, J.W. Mouton, I. Odenholt, A. Rodloff, C.J. Soussy, M. Steinbakk, F. Soriano, and O. Stetsiouk European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing Clin. Microbiol. Infect. 12 2006 501 503 (Pubitemid 43740760)
40. Marin H. Kollef Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin. Infect. Dis. 43 2006 S82 S88
41. A. Kumar, N. Safdar, S. Kethireddy, and D. Chateau A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta- regression study Crit. Care Med. 38 2010 1651 1664
42. A. Kumar, R. Zarychanski, B. Light, J. Parrillo, D. Maki, D. Simon, D. Laporta, S. Lapinsky, P. Ellis, Y. Mirzanejad, G. Martinka, S. Keenan, G. Wood, Y. Arabi, D. Feinstein, P. Dodek, L. Kravetsky, and S. Doucette Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis Crit. Care Med. 38 2010 1773 1785
43. J.E. Leggett, B. Fantin, S. Ebert, K. Totsuka, B. Vogelman, W. Calame, H. Mattie, and W.A. Craig Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models J. Infect. Dis. 159 1989 281 292 (Pubitemid 19049368)
44. B.R. Levin, and M.J.M. Bonten Cycling antibiotics may not be good for your health Proc. Natl. Acad. Sci. USA 101 2004 13101 13102 (Pubitemid 39209626)
45. C. Lienhardt, and G. Davies Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities Int. J. Tuberc. Lung Dis. 14 2010 528 537
46. L.M. Lim, N. Ly, D. Anderson, J.C. Yang, L. Macander, A. Jarkowski 3rd, A. Forrest, J.B. Bulitta, and B.T. Tsuji Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing Pharmacotherapy 30 2010 1279 1291
47. D.M. Livermore Minimising antibiotic resistance Lancet Infect. Dis. 5 2005 450 459 (Pubitemid 40840735)
48. A. Louie, C. Grasso, N. Bahniuk, B. Van Scoy, D.L. Brown, R. Kulawy, and G.L. Drusano The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression Antimicrob. Agents Chemother. 54 2010 2646 2654
49. M. Lutters, and N. Vogt Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women Cochrane Database Syst. Rev. 2002 3
50. J.K. Mak, M.J. Kim, J. Pham, J. Tapsall, and P.A. White Antibiotic resistance determinants in nosocomial strains of multidrug-resistant Acinetobacter baumannii J. Antimicrob. Chemother. 63 2009 47 54
51. MASTIN study group, P.M. A. S. C. T. M. p.s.; 2002. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet, 360, 835-841.
52. E. Meyer, M. Lapatschek, A. Bechtold, G. Schwarzkopf, P. Gastmeier, and F. Schwab Impact of restriction of third generation cephalosporins on the burden of third generation cephalosporin resistant K. pneumoniae and E. coli in an ICU Intens. Care Med. 35 2009 862 870
53. E. Miro, C. Segura, F. Navarro, L. Sorli, P. Coll, J.P. Horcajada, F. Alvarez-Lerma, and M. Salvado Spread of plasmids containing the bla(VIM-1) and bla(CTX-M) genes and the qnr determinant in Enterobacter cloacae, Klebsiella pneumoniae and Klebsiella oxytoca isolates J. Antimicrob. Chemother. 65 2010 661 665
54. M.J. Mooij, I. Willemsen, M. Lobbrecht, C. Vandenbroucke-Grauls, J. Kluytmans, and P.H. Savelkoul Integron class 1 reservoir among highly resistant gram-negative microorganisms recovered at a Dutch teaching hospital Infect Control Hosp. Epidemiol. 30 2009 1015 1018
55. J.W. Mouton Combination therapy as a tool to prevent emergence of bacterial resistance Infection 27 1999 S24 S28
56. J.W. Mouton Impact of pharmacodynamics on breakpoint selection for susceptibility testing Infect. Dis. Clin. North Am. 17 2003 579 598 (Pubitemid 38029154)
57. J.W. Mouton, M.N. Dudley, O. Cars, H. Derendorf, and G.L. Drusano Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update J. Antimicrob. Chemother. 55 2005 601 607 (Pubitemid 40691835)
58. J.W. Mouton, A. Schmitt-Hoffmann, S. Shapiro, N. Nashed, and N.C. Punt Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141 Antimicrob. Agents Chemother. 48 2004 1713 1718 (Pubitemid 38544379)
59. J.W. Mouton, M.L. van Ogtrop, D. Andes, and W.A. Craig Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo Antimicrob. Agents Chemother. 43 1999 2473 2478 (Pubitemid 29471230)
60. S. Nijssen, M. Bootsma, and M. Bonten Healthcare epidemiology: potential confounding in evaluating infection-control interventions in hospital settings: changing antibiotic prescription Clin. Infect. Dis. 43 2006 616 623 (Pubitemid 44267124)
61. S. Nijssen, A. Fluit, D. van de Vijver, J. Top, R. Willems, and M. Bonten Effects of reducing beta-lactam antibiotic pressure on intestinal colonization of antibiotic-resistant gram-negative bacteria Intens. Care Med. 36 2010 512 519
62. E. O'Fallon, A. Pop-Vicas, and E. D'Agata The emerging threat of multidrug-resistant gram-negative organisms in long-term care facilities J. Gerontol. A: Biol. Sci. Med. Sci. 64 2009 138 141
63. I.N. Okeke, R.W. Peeling, H. Goossens, R. Auckenthaler, S.S. Olmsted, J. de Lavison, B.L. Zimmer, M.D. Perkins, and K. Nordqvist Diagnostics as essential tools for containing antibacterial resistance Drug Resistance Updates. 14 2011 79 87
64. A. Oliver Mutators in cystic fibrosis chronic lung infection: prevalence, mechanisms, and consequences for antimicrobial therapy Int. J. Med. Microbiol. 300 2010 563 572
65. A. Oliver, R. Canton, P. Campo, F. Baquero, and J. Blazquez High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection Science 288 2000 1251 1254
66. M. Paul, I. Benuri-Silbiger, K. Soares-Weiser, and L. Leibovici Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials BMJ 328 2004 668
67. V. Plasencia, N. Borrell, M.D. Macia, B. Moya, J.L. Perez, and A. Oliver Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents Antimicrob. Agents Chemother. 51 2007 2574 2581 (Pubitemid 47047339)
68. S.H. Podolsky Antibiotics and the social history of the controlled clinical trial, 1950-1970 Journal of the History of Medicine and Allied Sciences 2010 65
69. E. Raineri, L. Crema, S. Dal Zoppo, A. Acquarolo, A. Pan, G. Carnevale, F. Albertario, and A. Candiani Rotation of antimicrobial therapy in the intensive care unit: impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria Eur. J. Clin. Microbiol. Infect. Dis. 29 2010 1015 1024
70. L.B. Rice The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile Clin. Infect. Dis. 46 2008 491 496 (Pubitemid 351263484)
71. J.L. Rodriguez-Tudela, B. Almirante, D. Rodriguez-Pardo, F. Laguna, J.P. Donnelly, J.W. Mouton, A. Pahissa, and M.C. Estrella Correlation of the MIC and Dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidaemia Antimicrob. Agents Chemother. 51 2007 3599 3604 (Pubitemid 47519349)
72. N. Safdar, J. Handelsman, and D.G. Maki Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis Lancet Infect Dis 4 2004 519 527 (Pubitemid 39077923)
73. A. Sandiumenge, E. Diaz, A. Rodriguez, L. Vidaur, L. Canadell, M. Olona, M. Rue, and J. Rello Impact of diversity of antibiotic use on the development of antimicrobial resistance J. Antimicrob. Chemother. 57 2006 1197 1204 (Pubitemid 44644425)
74. F. Saxer, A. Widmer, J. Fehr, I. Soka, P. Kibatala, H. Urassa, R. Frei, T. Smith, and C. Hatz Benefit of a single preoperative dose of antibiotics in a sub-Saharan district hospital: minimal input, massive impact Ann. Surg. 249 2009 322 326
75. F. Scaglione, J.W. Mouton, R. Mattina, and F. Fraschini Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios Antimicrob. Agents Chemother 47 2003 2749 2755 (Pubitemid 37040243)
76. P. Schulz zur Wiesch, J. Engelstadter, and S. Bonhoeffer Compensation of fitness costs and reversibility of antibiotic resistance mutations Antimicrob. Agents Chemother. 54 2010 2085 2095
77. M. Souli, I. Galani, and H. Giamarellou Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe Euro Surveill. 2008 13
78. L.E. Stearne, W.H. Goessens, J.W. Mouton, and I.C. Gyssens Effect of dosing and dosing frequency on the efficacy of cefizoxime and the emergence of ceftizoxime resistance during the early development of Bacteroides fragilis/Enterobacter cloacae mixed infection murine abscesses Antimicrob. Agents Chemother. 2007
79. R. Sykes The 2009 Garrod lecture: the evolution of antimicrobial resistance: a Darwinian perspective J. Antimicrob. Chemother. 65 2010 1842 1852
80. V.H. Tam, E.A. Gamez, J.S. Weston, L.N. Gerard, M.T. Larocco, J.P. Caeiro, L.O. Gentry, and K.W. Garey Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint Clin. Infect. Dis. 46 2008 862 867 (Pubitemid 351417187)
81. V.H. Tam, A. Louie, M.R. Deziel, W. Liu, R. Leary, and G.L. Drusano Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa J Infect Dis 192 2005 420 428 (Pubitemid 41023120)
82. V.H. Tam, A. Louie, T.R. Fritsche, M. Deziel, W. Liu, D.L. Brown, L. Deshpande, R. Leary, R.N. Jones, and G.L. Drusano Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial J Infect Dis 195 2007 1818 1827 (Pubitemid 46870255)
83. V.H. Tam, A. Louie, M.R. Deziel, W. Liu, and G.L. Drusano The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance Antimicrob. Agents Chemother. 51 2007 744 747 (Pubitemid 46185299)
84. D.T. Tsukayama, H.J. van Loon, C. Cartwright, B. Chmielewski, A.C. Fluit, C. van der Werken, and J. Verhoef The evolution of Pseudomonas aeruginosa during antibiotic rotation in a medical intensive care unit: the RADAR-trial Int. J. Antimicrob. Agents 24 2004 339 345 (Pubitemid 39369478)
85. H.J. van Loon, M.R. Vriens, A.C. Fluit, A. Troelstra, C. van der Werken, J. Verhoef, and M.J.M. Bonten Antibiotic rotation and development of gram-negative antibiotic resistance Am. J. Respir. Crit. Care Med. 171 2005 480 487 (Pubitemid 40444248)
86. L. Vinue, Y. Saenz, B. Rojo-Bezares, I. Olarte, E. Undabeitia, S. Somalo, M. Zarazaga, and C. Torres Genetic environment of sul genes and characterisation of integrons in Escherichia coli isolates of blood origin in a Spanish hospital Int. J. Antimicrob. Agents 35 2010 492 496